Substituted chromenones, IRE1 inhibitors, and methods of using same
View Patent ↗The present invention includes substituted chromenones that are useful to inhibit the IRE1/XBP-1 pathway. In certain embodiments, the compounds of the invention inhibit IRE1's RNase activity. In other embodiments, the compounds of the invention are useful to treat or prevent a cancer that involve activation of the ER stress response. The invention also relates, in certain aspects, to the discovery that secretory IgM (sIgM) can orchestrate an immunosuppressive microenvironment by recruiting myeloid-derived suppressor cells (MDSCs) into different tumor models, such as but not limited to solid tumors (such as but not limited to lung cancer) and tumors that have high levels of secreted IgM. In certain embodiments, sIgM produced by B cells or CLL cells can contribute to the accumulation of MDSCs in a tumor. In other embodiments, inhibition of the IRE1/XBP-1 pathway can ablate, minimize, or reduce MDSC levels in a tumor.
1. A compound of formula (I), or a salt or solvate thereof:
wherein:
R 1 is selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, HC(═O)—, (C 1 -C 6 alkyl)-C(═O)—, (C 2 -C 6 alkenyl)-C(═O)—, (C 2 -C 6 alkynyl)-C(═O)—, (C 3 -C 8 cycloalkyl)-C(═O)—, (C 1 -C 6 alkyl)-OC(═O)—, (C 2 -C 6 alkenyl)-OC(═O)—, (C 2 -C 6 alkynyl)-OC(═O)—, and (C 3 -C 8 cycloalkyl)-OC(═O)—,
wherein the alkyl, alkenyl, alkynyl, or cycloalkyl are independently optionally substituted;
R 2 is selected from the group consisting of optionally substituted 1,3-dioxolan-2-yl, optionally substituted 1,3-dioxan-2-yl, —CH═N—OR 5 , and —CH═N—NR 5 R 6 , wherein:
R 5 is selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, HC(═O)—, (C 1 -C 6 alkyl)-C(═O)—, (C 2 -C 6 alkenyl)-C(═O)—, (C 2 -C 6 alkynyl)-C(═O)—, and (C 3 -C 8 cycloalkyl)-C(═O)—, wherein the alkyl, alkenyl, alkynyl, or cycloalkyl are independently optionally substituted, and
R 6 is selected from the group consisting of H and C 1 -C 6 alkyl, wherein the alkyl is optionally substituted,
or R 5 and R 6 combine with the N atom to which they are bound to form an optionally substituted heterocyclyl or heteroaryl;
R 3 is —OH or a group that can be deprotected in vitro or in vivo to —OH; and
R 4 is selected from the group consisting of C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 3 -C 8 cycloalkoxy, HC(═O)O—, (C 1 -C 6 alkyl)-C(═O)O—, (C 2 -C 6 alkenyl)-C(═O)O—, (C 2 -C 6 alkynyl)-C(═O)O—, and (C 3 -C 8 cycloalkyl)-C(═O)O—,
wherein the alkyl, alkenyl, alkynyl, or cycloalkyl are independently optionally substituted.
2. The compound of claim 1 , wherein at least one applies:
each heterocyclyl is independently selected from the group consisting of imidazolyl, dihydroimidazolyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, and tetrahydropyrimidinyl;
each heteroaryl is independently selected from the group consisting of pyridinyl, pyrimidinyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, and triazolyl.
3. The compound of claim 1 , wherein at least one applies:
each occurrence of alkyl, alkenyl, alkynyl, or cycloalkyl is independently optionally substituted with at least one substituent selected from the group consisting of C 1 -C 6 alkyl, halogen, —CN, —OR, phenyl, and —N(R)(R),
wherein each occurrence of R is independently H, C 1 -C 6 alkyl, or C 3 -C 8 cycloalkyl;
each occurrence of phenyl, heterocyclyl, or heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, halogen, —CN, —C(═O)OR, —OR, —N(R)(R), —NO 2 , —S(═O) 2 N(R)(R), acyl, and C 1 -C 6 alkoxycarbonyl,
wherein each occurrence of R is independently H, C 1 -C 6 alkyl, or C 3 -C 8 cycloalkyl.
4. The compound of claim 1 , wherein R 2 is selected from the group consisting of:
5. The compound of claim 1 , wherein R 3 is a group that can be deprotected in vitro or in vivo to —OH.
6. The compound of claim 5 , wherein R 3 is selected from the group consisting of optionally substituted o-nitrobenzyloxy groups, optionally substituted benzoin groups, (OH) 2 B— and any ether derivatives thereof, optionally substituted boronobenzyl groups and any ether derivatives thereof, optionally substituted aryl-S(═O) 2 O— or heteroaryl-S(═O) 2 O— groups, and optionally substituted acyloxy or aryloxy groups.
7. The compound of claim 1 , which is selected from the group consisting of:
8. A compound selected from the group consisting of:
or a salt or solvate thereof.
9. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and the compound of claim 1 .
10. The pharmaceutical composition of claim 9 , further comprising at least one additional anticancer agent selected from the group consisting of ibrutinib, bortezomib, carfilzomib, ixazomib, lactacystin, disulfiram, epigallocatechin-3-gallate, marizomib, oprozomib (ONX-0912), delanzomib (CEP-18770), epoxomicin, beta-hydroxy beta-methylbutyrate, or a solvate or salt thereof.
11. A compound of formula (I), or a salt or solvate thereof:
wherein:
R 1 is selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, HC(═O)—, (C 1 -C 6 alkyl)-C(═O)—, (C 2 -C 6 alkenyl)-C(═O)—, (C 2 -C 6 alkynyl)-C(═O)—, (C 3 -C 8 cycloalkyl)-C(═O)—, (C 1 -C 6 alkyl)-OC(═O)—, (C 2 -C 6 alkenyl)-OC(═O)—, (C 2 -C 6 alkynyl)-OC(═O)—, and (C 3 -C 8 cycloalkyl)-OC(═O)—,
wherein the alkyl, alkenyl, alkynyl, or cycloalkyl are independently optionally substituted;
R 2 is selected from the group consisting of 1,3-dioxolan-2-yl, 5-methyl-1,3-dioxan-2-yl, 5,5-dimethyl-1,3-dioxan-2-yl, —CH═N—OR 5 , and —CH═N—NR 5 R 6 , wherein:
R 5 is selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, HC(═O)—, (C 1 -C 6 alkyl)-C(═O)—, (C 2 -C 6 alkenyl)-C(═O)—, (C 2 -C 6 alkynyl)-C(═O)—, and (C 3 -C 8 cycloalkyl)-C(═O)—,
wherein the alkyl, alkenyl, alkynyl, or cycloalkyl are independently optionally substituted, and
R 6 is selected from the group consisting of H and C 1 -C 6 alkyl, wherein the alkyl is optionally substituted,
or R 5 and R 6 combine with the N atom to which they are bound to form an optionally substituted heterocyclyl or heteroaryl;
R 3 is —OH or a group that can be deprotected in vitro or in vivo to —OH; and
R 4 is selected from the group consisting of H, —OH, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 3 -C 8 cycloalkoxy, HC(═O)O—, (C 1 -C 6 alkyl)-C(═O)O—, (C 2 -C 6 alkenyl)-C(═O)O—, (C 2 -C 6 alkynyl)-C(═O)O—, and (C 3 -C 8 cycloalkyl)-C(═O)O—,
wherein the alkyl, alkenyl, alkynyl, or cycloalkyl are independently optionally substituted.
12. The compound of claim 11 , wherein at least one applies:
each heterocyclyl is independently selected from the group consisting of imidazolyl, dihydroimidazolyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, and tetrahydropyrimidinyl;
each heteroaryl is independently selected from the group consisting of pyridinyl, pyrimidinyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, and triazolyl.
13. The compound of claim 11 , wherein at least one applies:
each occurrence of alkyl, alkenyl, alkynyl, or cycloalkyl is independently optionally substituted with at least one substituent selected from the group consisting of C 1 -C 6 alkyl, halogen, —CN, —OR, phenyl, and —N(R)(R),
wherein each occurrence of R is independently H, C 1 -C 6 alkyl, or C 3 -C 8 cycloalkyl;
each occurrence of phenyl, heterocyclyl, or heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, halogen, —CN, —C(═O)OR, —OR, —N(R)(R), —NO 2 , —S(═O) 2 N(R)(R), acyl, and C 1 -C 6 alkoxycarbonyl,
wherein each occurrence of R is independently H, C 1 -C 6 alkyl, or C 3 -C 8 cycloalkyl.
14. The compound of claim 11 , wherein R 2 is selected from the group consisting of:
15. The compound of claim 11 , wherein R 3 is a group that can be deprotected in vitro or in vivo to —OH.
16. The compound of claim 15 , wherein R 3 is selected from the group consisting of optionally substituted o-nitrobenzyloxy groups, optionally substituted benzoin groups, (OH) 2 B— and any ether derivatives thereof, optionally substituted boronobenzyl groups and any ether derivatives thereof, optionally substituted aryl-S(═O) 2 O— or heteroaryl-S(═O) 2 O— groups, and optionally substituted acyloxy or aryloxy groups.
17. The compound of claim 11 , which is selected from the group consisting of:
or a salt or solvate thereof.
18. A compound selected from the group consisting of
or a salt or solvate thereof.
19. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and the compound of claim 11 .
20. The pharmaceutical composition of claim 19 , further comprising at least one additional anticancer agent selected from the group consisting of ibrutinib, bortezomib, carfilzomib, ixazomib, lactacystin, disulfiram, epigallocatechin-3-gallate, marizomib, oprozomib (ONX-0912), delanzomib (CEP-18770), epoxomicin, beta-hydroxy beta-methylbutyrate, or a solvate or salt thereof.